Safety and Immimogenicity of a Candidate HIV-1 Vaccine in Healthy Adults: Recombinant Glycoprotein (rgp) 120: A Randomized, Double-Blind Trial

Annals of Internal Medicine

Volumn 125, Issue 4, 1996, Pages 270-279

  Graham, Barney S ^a   Keefer, Michael C ^b   McElrath, M Juliana ^c   Gorse, Geoffrey J ^d   Schwartz, David H ^e   Weinhold, Kent ^f   Matthews, Thomas J ^f   Esterlitz, Joy R ^g   Sinangil, Faruk ^h   Fast, Patricia E ⁱ   Wright, Peter F ^a   Dolin, Raphael ^b   Corey, Lawrence ^c   Belshe, Robert B ^d   Clements, Mary Lou ^e   Bolognesi, Dani P ^f   Stablein, Donald M ^g   Chernoff, David ^h   Duliège, Anne Marie ^h   Walker, Christopher M ^h  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g EMMES CORPORATION   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOLOGY; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SERODIAGNOSIS; T LYMPHOCYTE;

ADULT; AIDS VACCINES; DOUBLE-BLIND METHOD; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV SERONEGATIVITY; HIV-1; HUMANS; IMMUNIZATION SCHEDULE; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; REFERENCE VALUES; T-LYMPHOCYTES;

EID: 0030586434     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-4-199608150-00003     Document Type: Article

References (37)

1. Hilleman MR, McAleer WJ, Buynak EB, McLean AA. The preparation and safety of hepatitis B vaccine. J Infect. 1983;7 (Suppl 1):3-8.
2. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992;355:728-30.
3. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 1990;345: 622-5.
4. Girard M, Kieny MP, Pinter A, Barre-Sinoussi F, Nara P, Kolbe H, et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 1991;88:542-6.
5. SF2. AIDS. 1995;9:1313-22.
6. Kniker WT, Anderson CT, Roumeantzeff M. The multi-test system: a standardized approach to evaluation of delayed hypersensitivity and cell-mediated immunity. Ann Allergy. 1979;43:73-9.
7. Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis. 1993;167:533-7.
8. Skinner MA, Langlois AJ, McDanal CB, McDougal JS, Bolognesi DP, Matthews TJ. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol. 1988;62:4195-200.
9. Lyerly HK, Matthews TJ, Langlois AJ, Bolognesi DP, Weinhold KJ. Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci USA. 1987;84:4601-5.
10. Weinhold KJ. Non-MHC restricted forms of anti-HIV-1 cytotoxicity: antibody-dependent cellular cytotoxicity (ADCC) and cell-mediated cytotoxicity (CMC). In: Aldovini A, Walker BD, eds. Techniques in HIV Research. New York: Stockton Pr; 1990: 187-99.
11. Keefer MC, Bonnez W, Roberts NJ Jr, Dolin R, Reichman RC. Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients. J Infect Dis. 1991;163:448-53.
12. Dolin R, Graham BS, Greenberg SB, Tackelt CO, Belshe RB, Midthun K, et al. Safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med. 1991;114:119-27.
13. Belshe RB, Clements ML, Dolin R, Graham BS, McElrath MJ, Gorse GJ, et al. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subject at low risk of infection. NIAID AIDS Vaccine Evaluation Group Network. J Infect Dis. 1993;168: 1387-95.
14. Keefer MC Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP, et al. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. AIDS Res Hum Retroviruses. 1994;10:1713-23.
15. Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA. 1994;272:475-80.
16. Schwartz DH, Gorse G, Clements ML, Belshe R, Izu A, Duliege AM, et al. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. NIAID AIDS Clinical Trials Network. Lancet. 1993;342:69-73.
17. Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Sposto R, Corey L, et al. Safety and immunogenicity of env2-3, a human immunodeficiency virus type-1 candidate vaccine in combination with MTP-PE/MF59. NIAID AIDS Clinical Trials Network. AIDS Res Hum Retroviruses. 1996;12:683-93.
18. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993;67:6642-7.
19. Wintsch J, Chaignat CL, Braun DG, Jeannet M, Stalder H, Abrignani S, et al. Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J Infect Dis. 1991;163:219-25.
20. Steimer KS, Scandella O, Skiles PV, Haigwood NL. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 1991;254:105-8.
21. Haigwood NL, Nara PL, Brooks E, Van Nest GA, Ott G, Higgins KW, et al. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J Virol. 1992;66:172-82.
22. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Clements ML, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. NIAID AIDS Vaccine Evaluation Group. J Infect Dis. 1996;173:340-8.
23. Sullivan N, Sun Y, Li I, Hofmann W, Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol. 1996; 69:4413-22.
24. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol. 1993;151:2032-40.
25. Tang YW, Graham BS. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest. 1994;94: 1953-8.
26. Van Nest GA, Steimer KS, Halgwood NL, Burke RL, Ott G. Advanced adjuvant formulations for use with recombinant subunit vaccines. Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1992: 57-62.
27. Bui T, Dykers T, Hu SL, Faltynek CR, Ho RJ. Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein. J Acquir Immune Defic Syndr. 1994;7:799-806.
28. Walker CM. Priming of cytotoxic T lymphocyte responses with recombinant HIV envelope proteins in murine and primate models. Huitième Colloque des Cent Gardes. 1993: 321-5.
29. Koup RA, Safrit FU, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68:4650-5.
30. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994;68: 6103-10.
31. Reimann KA, Tenner-Racz K, Racz P, Montefiori DC Yasutomi Y, Lin W, et al. Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol. 1994;68:2362-70.
32. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med. 1995;1:59-64.
33. Lanzavecchia A. Identifying strategies for immune intervention. Science. 1993;260:937-44.
34. Kahn JO, Sinangil F, Baenziger J, Murcar N, Wynne D, Coleman RL, et al. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1 SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis. 1994;170:1288-91.
35. Gorse GJ, Schwartz DH, Graham BS, Matthews TJ, Stablein DM, Frey SE, et al. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network. Clin Exp Immunol. 1994;98: 178-84.
36. Belshe RB, Clements ML, Keefer MC, Graham BS, Corey L, Sposto R, et al. Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med. 1994; 121:584-9.
37. Kahn JO, Steimer KS, Baenziger J, Duliege AM, Feinberg M, Elbeik T, et al. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. J Infect Dis, 1995;171:1343-7.